参考引用文献 | 西新宿レディースクリニック

(1) 日産婦誌61巻６号
(2) 子宮頸がん啓発のための学術情報冊子　「HPVInsight}　第１号
(3) 子宮頸がん啓発のための学術情報冊子　「HPVInsight}　第２号
(4) 子宮頸がん啓発のための学術情報冊子　「HPVInsight}　第３号
(5) サーバリックスを正しく接種していただくために
(6) Medical　Tribune　2009年11月5日号
(7) グラクソ・スミスクライン株式会社　小冊子
(8) Medical　Asahi　2009　december
(9) Medical　Tribune　1692号
(10) 日本細胞診断学推進協会　子宮頸がん検診とヒトパピローマウイルス　Q&A集
(11) Sonnex C, Strauss S, Gray JJ. Detection of human papillomavirus DNA on Ule丘ngers of patients widl genital warts. Sex Transm Infect,1999,75:317-319.
(12) Dunne EF, Unger ER. Sternberg M, et al. Prevalence of HPV infection among females in the United States. JAMA,2007,297:813-819.
(13) Maehama T, Asato T, Kanazawa K. Prevalence of nPV infection in cervical cytology＿normal women in Okinawa, Japan, as determined by a polymerase chain reaction. Int J Gynecol Obstet 2000,69:175- 176.
(14) Inoue M, Sakaguchi J, Sasagawa T, et al. The evaluation of human papillomavirus DNA testing in Primary screening for cervical lesions in a large Japanese popula伍on. Int J Gynecol Cancer,2006,16: 1007-1013.
(15) Ho GY, Bierman R, Beardsley L, et al. Natural history of cervicovaginal papillomavirus infec伍on in young women. N Engl J Med,1998,338:423-428.
(16) Winer RL, Lee SK, Hughs Jp, et aL Genital human papillomavirus infection:incidence and risk factors in a cohort of female university students. Am J Epidemiol,2003,157:218-226.
(17) Woodman CB, Collins S, Winter H, et al. Natural history of cervical human papillomavirus infection in young women:alongitudinal cohort study. LanceL 2001,357:1831-1836.
(18) Guiliano AR, Harris R, Sedjo RL, et al. Incidence, prevalence, and clearance of type-specific human papnlomavirus infec伍on:The young Women's Health Study. J Infect Dis,2001,186:452-469.
(19) Molano M, Van den Burle A, Plummer M, et al. Determinants of clearance of human papilloma摘nls infection in Colombian women with normal cytology:apopulation・based,5・year follow-up study. Am J
(20) 赤松節.姫路由香里,長澤優子,他.子宮頭がん検診標本の適否状況一Thinlayer法と従来法の比較. 日臨細胞学会誌,2005,44:63＿68.
(21) 伊地知徹,下口幸夫,名取恒夫.A.精度管理1.細胞診断の自動化・1-ThinLayer標本による標準化一.臨床病理レビュー特集,2005,132:49-54.
(22) 飯塚千祥,平井康夫,川又靖貴,他.子宮頭部液状処理細胞診(Liquid-Based Cytology:LBC)の子宮頭部病変検出に関する前方視的研究.日癌治誌,2008,43:405.
(23) McGoogan E, Reith A. Would monolayers provide more representative samples and improved preparations for cervical screening?Overview and evaluation of systems available. Acta Cytol,1996, 40:107-119.
(24) Dowie R, Stoykova B, Crawford D, et al. Liquid・based cytology can improve efficiency of cervical smear readers:evidence irom timing surveys in two NHS cytology laboratories. Cytopathology,2006, 17(2):65-72.
(25) 齋藤深雪,長島義男.8.病理・細胞診検査機器10)細胞診自動塗抹装置.Medical Technology,2006, 34:1622-1625.
(26) Namce KV. Evolution of Pap testing at a community hospital:aten・year experience. Diagn Cytopathology,2007,35:148-153.
(27) 赤松節,姫路由香里,生田直美,他.子宮頭がん検診標本の適否状況とその発見病変一Liquid-based cytology法とconventional法の比較一.日臨細胞誌,2008,47:420-424.
(28) Hutchinson ML, Hutchinson ML, Isenstein LM, et al. Homogeneous sampling accounts for theKnoepp SM, Kuebler DL, Wilbur DC. Resolu伍on of equiv㏄al results with the Hybrid Capture II high- risk HPV DNA tesセacytologic/histologic review of 191 cases. Diagn Mol PathoL 2007,16:125-129.
(29) 平井康夫.子宮頚癌の予防・早期発見のための検査手順(トリアージ:triage).臨床検査,2007,51: 817-822.
(30) Depuydt CE, Benoy IH, Bailleul EJ, et al. Improved endocervical sampling and HPV vial load detec伍on by Cervex-Brush Combi. Cytopathology,2006,17:74-81.
(31) 赤松節,姫路由香里,松田真由美,他.子宮がん集団検診における細胞採取器具の評価.日臨細胞誌, 2004,43:161-165.
(32) 手塚文明,秀城浩司,及川洋恵,他.子宮頚部から擦過採取される細胞数とスライド標本に塗抹される細胞数.日臨細胞誌,1994,33:463＿467.
(33) Bigras G,Rieder MA, Lambercy JM, et al. Keeping conec伍ng device in liquid medium is mandatory to opdmized liquid-based cervical cytologic sampling. J Lower Genital Tract Disease,2003,7:10S-174.
(34) 中村博,古谷津純一,石和久.Thinlayer法とその見方. Medical Technology,2005,33:293-298.
(35) 中木龍夫,原田俊英,立山義朗.アンケート結果による広島県における子宮頭がん検診の現状と問題点の評価.日がん検診・診断会誌,2009,16:77-82.
(36) Kulasingam SL, Kim JJ, Lawrence WF, et al. Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance!low-grade squamous intraepithelial lesion triage study (ALTS).JNad Cancer Inst 2006,98:92-IOO.
(37) Bidus MA, Maxwell GL, Kulasingam S, et al. Cost-effective analysis of liquid＿based cytology andHPVテストとコルポ診,二次検診法の是非(Q35～36)
(38) Wright TC Jr. Cervical cancer screening in the 21st century:is it伍me to re伍re the PAP smear?Clin Obstet Gynecol,2007,50:313-323.
(39) Wright Jr L, Massad C, Dunton M. et al.2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Reviews Oncology, Amer J Obstet GynecoL 2007,197: 346-355.
(40) CastelisaguE X, Diaz M, de SanjosE S, et al. International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J rtatl Cancer Inst, 2006,98 : 303-315.
(41) Zielinski GD, Snijders PJ, Rozendaal L, et al. The presence of high-risk HPV combined with specific p53 and p16IrtK4a expression patterns points to high-risk HPV as the main causative agent for adenocarcinoma in situ and adenocarcinoma of the cervix. J PathoL 2oo3,201 : 535-543.
(42) Rabel0-Santos SH, Derchain SF, do Amaral Westin MC, et al. Endocervical glandular cell abnormalities in conventional cervical smears: evaluation of the periormance of cytomorphological criteria and HPV testing in predicting neoplasia. Cytopathology, 2000, l9 : 34-43.
(43) Costa S, legri G, Sideri M, et al. Human papillomavirus(HPV)test and PAP smear as predictors of outcome in conservatively treated adenocarcinoma in situ(AIS)of the uterine cervix. Gynecol 0ncol, 2oo7,106 : 170-176.
(44) Nakagawa S, Yoshikawa H, Onda T, et aL Type of human papinomavirus is related to clinical features of cervical carcinoma. Cancer,1996,78:1935-1941,
(45) 今野良,笹川寿之,福田敬,他.日本人女性における子宮頭癌予防ワクチンの費用効果分析.産婦治療,2008,97:530-542.
(46) FUTURE n Study Group. Prophylactic emcacy of a quadrivalent human papillomavirus(HPV)vaccine in women with virological evidence of HPV infection. J Infect Dis,2007,196:1438-1446.
(47) Smith JS, Lindsay L, Hoots B, et aL Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions:ameta-analysis update, Int J Cancer,2007,121:621-632.
(48) Cli丘ord GM, Smith JS, Plummer M, et al. Human papillomavirus types in invasive cervical cancer worldwide:ameta-analysis. Br J Cancer,2003,88:63-73.